{"version":"1.0","provider_name":"Avalere Health Advisory","provider_url":"https:\/\/advisory.avalerehealth.com","title":"White Paper: Valuing Multi-Use Drugs in Medicare Negotiation | Avalere Health Advisory","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"kxAlE4Tbdf\"><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/white-paper-valuing-multi-use-drugs-in-medicare-negotiation\">White Paper: Valuing Multi-Use Drugs in Medicare Negotiation<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/advisory.avalerehealth.com\/insights\/white-paper-valuing-multi-use-drugs-in-medicare-negotiation\/embed#?secret=kxAlE4Tbdf\" width=\"600\" height=\"338\" title=\"&#8220;White Paper: Valuing Multi-Use Drugs in Medicare Negotiation&#8221; &#8212; Avalere Health Advisory\" data-secret=\"kxAlE4Tbdf\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2022\/09\/27279-1-MichaelCiarametaro-400x600-1.jpg","thumbnail_width":600,"thumbnail_height":400,"description":"Click here to access the white paper. In 2026, the maximum fair prices (MFPs) for the first set of selected drugs under the Medicare Drug Price Negotiation Program will go into effect. Additionally, on January 17, 2025, the Centers for Medicare &amp; Medicaid Services (CMS) released the list of the next 15 drugs selected for&hellip;"}